AGT 100216
Alternative Names: AGT-100216Latest Information Update: 09 Jul 2024
At a glance
- Originator Augustine Therapeutics
- Class Small molecules
- Mechanism of Action HDAC6 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Charcot-Marie-Tooth disease; Peripheral neuropathies
Most Recent Events
- 26 Jun 2024 Preclinical trials in Charcot-Marie-Tooth disease in Belgium (PO) prior to June 2024
- 26 Jun 2024 Preclinical trials in Peripheral neuropathies in Belgium (PO) prior to June 2024
- 26 Jun 2024 Pharmacodynamics data from preclinical studies in Charcot-Marie-Tooth disease, were released by Augustine Therapeutics